Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, tolerability, and pharmacokinetics of desvenlafaxine SR in children and adolescents with major depressive disorder
2008-002066-57Phase 3
- Sponsor
- Wyeth
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of desvenlafaxine in major depressive disorder (MDD), sponsored by Wyeth. Primary endpoint: Safety and tolerability from baseline to follow-up (up to Day 77).
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2008-002066-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002066-57.